Prostaglandin E2 possesses different potencies in inducing Vascular Endothelial Growth Factor and Interleukin-8 production in COPD human lung fibroblasts by A. Bonanno et al.
 
1 
Prostaglandin E2 possesses different potencies in inducing Vascular Endothelial Growth Factor and 
Interleukin-8 production in COPD human lung fibroblasts   
 
Anna Bonanno1*, Giusy Daniela Albano1*, Liboria Siena1,  
Angela Marina Montalbano1, Loredana Riccobono1, Giulia Anzalone1,  
Giuseppina Chiappara1, Rosalia Gagliardo1, Mirella Profita1, Angelo Sala2,1 
1 Institute of Biomedicine and Molecular Immunology “A. Monroy” (IBIM), National Research Council of 
Italy (CNR), Palermo, Italy 
2 Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. 
  
*AB and GDA equally contributed to this work. 
 
Corresponding Author: Angelo Sala, PhD 
Department of Pharmacological and Biomolecular Sciences, University of Milan, 
Via Balzaretti 9, 20133 Milano, Italy. 
ph: +39 02 50318308; fax +39 02 50318284 
e-mail: angelo.sala@unimi.it  
 
The authors acknowledge support from the National Research Council of Italy (CNR), Palermo, Italy  
																																								 																				
 Abbreviations: 
COPD: Chronic Obstructive Pulmonary Disease; COX: Cyclooxygenase; EP: E-prostanoid receptors; 
VEGF:vascular endothelial growth factor; IL-8: Interleukin 8; PGE2: prostaglandin E2 
 
2 
Summary 
We studied the role of PGE2, its biosynthetic enzymes and its receptors, in regulating the functions of lung 
fibroblasts through the production of Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) in 
COPD subjects. 
Lung fibroblasts from Control (C) (n=6), Smoker (HS) (n=6) and COPD patients (n=8) were cultured, and basal 
PGE2, VEGF, and IL-8 measured in supernatants by ELISA. COX-1/COX-2 and EP receptors expression were 
assessed by western blot and by RT-PCR. Release of VEGF and IL-8 by human fetal lung fibroblasts (HFL-1; 
lung, diploid, human) was evaluated under different conditions. 
PGE2, VEGF, and IL-8 levels, COX-2, EP2, and EP4 protein expression and mRNA were increased in COPD 
when compared to Controls. Low concentrations of synthetic PGE2 increased the release of VEGF in HFL-1, but 
higher concentrations were needed to induce the release of IL-8. This effect was mimicked by an EP2 agonist and 
modulated by an EP4 antagonist. 
In the airways of COPD subjects, fibroblast-derived PGE2 may regulate angiogenesis and inflammation through 
the production of VEGF and IL-8 respectively, suggesting that the increase in expression of COX-2, EP2 and EP4 
observed in COPD fibroblasts may contribute to steering the role of PGE2 from homeostatic to pro-inflammatory. 
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1. Introduction 
Prostaglandin E2 (PGE2), is a metabolite derived from arachidonic acid by the coordinated activity of 
cyclooxygenase and prostaglandin E synthase enzymes, and cigarette smoke is known to increase the expression of 
both cyclooxygenase-2 (COX-2) and prostaglandin E synthase in human fibroblasts [1]. PGE2 has the potential to 
function as both an autocrine and a paracrine mediator in fibroblasts, affecting chemotactic recruitment [2][3], 
proliferation [4], matrix production [5,6], and matrix remodeling [7,8]. PGE2 acts on four distinct G protein–
coupled E-prostanoid (EP) receptors named EP1, EP2, EP3, and EP4, [9,10], and coupled to different transduction 
mechanisms such as the increase in intracellular cyclic adenosine monophosphate (cAMP, EP2 and EP4), the 
decrease in cAMP (EP3), and the increase in intracellular calcium (EP1) [11][12]. Through the interaction with 
these receptors, PGE2 mediates a variety of physiologic responses [10,13,14].  
Alterations in fibroblast functions could play a role in the pathogenesis of pulmonary emphysema during COPD, 
which is characterized by inadequate maintenance of tissue structure [15]. Fibroblasts are a major source of 
vascular endothelial growth factor (VEGF), which modulates pulmonary microvasculature promoting the 
angiogenesis by alveolar endothelial cells. Prostacyclin analogues stimulate the production of VEGF by human 
lung fibroblasts, an effect mediated by the I-prostanoid receptor acting through the cAMP/protein kinase–A (PKA) 
pathway [16]. Similarly, it has recently been observed that PGE2 stimulates the production of VEGF through the 
activation of the Gs-coupled EP2 receptor in cultured human lung fibroblasts [4]. Furthermore, PGs are known to 
increase IL-8 release by fibroblasts [17], playing also a potentially important role in COPD airway chronic 
inflammation [18].  
In this study, we evaluated the release of PGE2, VEGF, and IL-8 as well as the expression of COX-2 and EP 
receptors in cultured fibroblasts obtained from COPD patients, smoker, and control subjects. Furthermore, since 
we observed a positive correlation between PGE2 concentrations and VEGF or IL-8 in the supernatants of cultured 
fibroblasts obtained from COPD patients, we studied the effect of PGE2 on VEGF and IL-8 production in human 
fibroblasts, in order to understand the potential contribution of PGE2 to angiogenesis and inflammation within the 
airways of COPD subjects. 
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2. Materials and Methods 
2.1. Study population 
Three groups of subjects who underwent lung resection for a solitary peripheral lung cancer were recruited: 
Chronic obstructive pulmonary disease (COPD) (n=8), asymptomatic smokers with normal lung function (n=6) 
(HS), and asymptomatic non-smoking subjects with normal lung function (n=6) (C). COPD patients were defined 
accordingly to the GOLD guidelines [19] and were classified as stage I-II (Mild to Moderate COPD). Patients with 
COPD and HS subjects had a smoking history of 10 pack years or more. Four of the COPD patients are former 
smokers and had quit smoking for at least 2 yr before the lung resection. All patients were characterized with 
respect to sex, age, smoking history, COPD symptoms, co-morbidities and current treatment. Exclusion criteria 
included the following: other systemic diseases, other lung diseases apart from COPD and lung tumors, upper 
respiratory tract infections and treatment with glucocorticoids or anticholinergics within the 3 months prior to the 
study. 
The study protocol was approved by the Ethic Committee (#217806-30/06/2008) and informed written consent 
was obtained from each patient. 
2.2. Pulmonary function tests. 
Pulmonary function tests were carried out according to the GOLD guidelines [19]. To assess the 
reversibility of the airway obstruction in subjects with a FEV1/FVC <70%, the FEV1 measurement was repeated 
15 minutes after the inhalation of 200 µg of salbutamol. 
2.3. Isolation and culture of lung fibroblasts from patients. 
Tumor free material and nontraumatic tissue from surgical specimens were used. Human lung fibroblasts 
were isolated from surgical specimens of human bronchi as previously described [20]. To confirm the purity of the 
cultured fibroblasts, the recovered cells were identified by their morphology, adherent nature, expression of 
vimentin and types I and III collagen, and lack of expression of cytokeratin, α-smooth muscle actin, factor VIII 
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and CD45. Immunoreactivity for these markers was revealed using the LSAB method (Dako LSAB®, 
Glostrup, Denmark) following the manufacturer’s instructions. 
Purified lung fibroblasts from COPD, HS, and C subjects were grown in a humidified atmosphere containing 5% 
CO2, and passaged by trypsinization at nearly confluence onto 100 mm culture plates as previously described [20]. 
Subsequently, after additional 24 hrs under FBS-free conditions (5% CO2 at 37°C), supernatants of monolayer 
cultures were harvested and stored at -80°C until assayed for basal PGE2, VEGF, and IL-8 levels. At the same time 
lung fibroblasts were detached and treated for protein and mRNA extraction. Only early passage cells (1-3) were 
used for each experiment to avoid problems that may occur in the higher number of cell passages and the 
biological analyses. 
2.4. Measurement of PGE2, VEGF, and IL-8. 
PGE2 levels were quantified by a commercial ELISA (GE Healthcare, Uppsala, Sweden) according to the 
manufacturer’s protocol. The detection limit was 40 pg/ml. VEGF and IL-8 were quantified in the supernatants of 
monolayer cultures by commercial ELISA kits (R&D Systems Europe Ltd, Abington, UK). Sensitivity was 5.0 
pg/ml and 3.5 pg/ml for VEGF and IL-8, respectively. Absorbance was measured using a Wallac 1420 Victor2 
multilabel counter (Perkin-Elmer Life Sciences, Turku, Finland). 
2.5. Western blot analyses of COX-1 and COX-2 proteins and EP receptors expression. 
Total protein extracts from cultured lung fibroblasts of COPD, control smoker and control subjects were 
resuspended in 2x Laemmli buffer and separated by SDS-PAGE followed by electroblotting onto nitrocellulose 
membranes for COX-1, COX-2, and EP receptors protein expressions. The following antibodies were used: a 
mouse monoclonal antibody direct against human COX-1 or COX-2 (Cayman Chem, MI, Italy), a rabbit 
polyclonal antibody directed against the human EP1, EP2, EP3 or EP4 receptor (Cayman Chem, MI, Italy). 
Primary antisera were visualized with HRP-conjugated secondary antibody (Sigma St. Louis, MO) and developed 
with an enhanced chemiluminescence system (Amersham Life Sciences UK Limited). Approximate molecular 
masses were determined using calibrated pre-stained standards (Amersham Life Sciences UK Limited). Negative 
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controls were performed in the absence of primary antibody or including an isotype control antibody. β-
actin (Sigma St. Louis, MO) was used as a housekeeping protein to normalize western blot analyses. Gel images 
were taken with an EPSON GT-6000 scanner and then imported to a National Institutes of Health Image analyses 
1.61 program to determine band intensity. Data are expressed as arbitrary densitometric units corrected against the 
density of β-actin bands. 
2.6. Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) of COX-2 and EP 
receptors. 
Total RNA was extracted from patient fibroblasts with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) 
following the manufacturer’s instructions, and was reverse-transcribed into cDNA, using M-MLV-RT and 
oligo(dT)12-18 primer (Invitrogen). Quantitative real-time PCR of the transcripts for COX-2 and for both EP2 and 
EP4 receptor subtypes of human PGE2 receptors was carried out on Step One Plus Real-time PCR System 
(Applied Biosystems, Foster City, CA, USA) using specific FAM-labeled probe and primers (prevalidated 
TaqMan Gene expression assay for COX-2, Hs00153133m1, and for EP2, and EP4 receptors, Assays on Demand, 
Applied Biosystems). Gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
control gene. Relative quantitation of gene expression level between C and HS or COPD subjects was evaluated 
with the comparative CT method (2-ΔΔCt). Relative expression levels were presented as the relative fold increase 
compared to the healthy subjects and calculated using the formula: 2 -ΔΔCT= 2-(ΔCT(HS or COPD) - ΔCT(C), 
where each ΔCT =ΔCTtarget-ΔCTGAPDH [21]. 
 
2.7. HFL-1 culture. 
Human fetal lung fibroblasts (HFL-1; lung, diploid, human) (from American Type Culture Collection, 
Manassas V.A.) were cultured in 100 mm tissue culture dishes (Falcon; Becton-Dickinson Labware, Lincoln Park, 
NJ) with RPMI1640 supplemented with 10% FCS, 2 mM glutamine, 25 mM HEPES buffer, 1% MEM non 
essential aminoacids, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2.5 µg/ml fungizone. Cells were refed 
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twice a week, subcultured weekly and maintained in 10% FCS RPMI1640. Fibroblasts between passages 15 
and 20 were used for all experiments. The HFL-1 cell line was used in the present study because of difficulty in 
obtaining sufficient quantities of primary human lung airway fibroblasts for these experiments. 
2.8. Stimulation of HFL-1 cells and PGE2 depletion in supernatants from lung fibroblasts. 
To evaluate the relationship between PGE2 concentration and the release of VEGF and IL-8, HFL-1 cells 
(1.5 x 106/ml) were plated in 100 mm tissue culture dishes for 18 hrs in the presence or absence of exogenous 
synthetic PGE2 at different concentrations (10-9 to 10-6 M, Sigma Aldrich, Milan, Italy). To test the contribution of 
different levels of paracrine PGE2 present in cultured lung fibroblast supernatants on VEGF and IL-8 release, 
HFL-1 cells (1.5 x 106/ml) were stimulated for 18 hrs in the presence or absence of selected supernatants with low 
(<10-9 M, n=3) or high (>10-8 M, n=3) PGE2 levels. Selected supernatants from lung fibroblasts were added diluted 
1:2 with culture medium for HFL-1 stimulation.  
To determine the specific effect of paracrine PGE2 present in cultured lung fibroblast supernatant on VEGF 
and IL-8, selected samples showing high (>10-8 M, n=3) PGE2 concentrations were incubated in the presence or 
absence of PGE2 affinity sorbent (mouse anti-PGE2 IgG covalently bound to Sepharose 4B) (Cayman Chemical). 
The affinity sorbent was used to eliminate the PGE2 from supernatants as previously described [22]. Finally, HFL-
1 cells were stimulated for 18 hrs with selected supernatants from lung fibroblast depleted of PGE2. 
To evaluate the role of EP receptors, we stimulated HFL-1 cell line with Butaprost (Sigma, 10-6 M, EP2 
agonist), Sulprostone (Sigma, 10-5 M, EP1/EP3 agonist)[23] or supernatants of lung fibroblasts from COPD in 
presence or absence of SC 19220 (Sigma, 10-5 M, EP1 antagonist) or AH23848 (Sigma, 10-5 M EP4 antagonist). 
Antagonists were added to the HFL-1 1 hr before the stimulation with supernatants of lung fibroblasts from COPD 
patients selected with a level of PGE2 >10-8 M. 
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2.9. Statistical analysis. 
Data are expressed as mean+SD. Statistical analysis for multiple comparison was carried out using Kruskal-
Wallis and Mann-Whitney U test or non parametric ANOVA tests followed by Fisher’s PLDS correction. A 
p<0.05 was considered as statistically significant. 
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3. Results 
3.1. Demographic characteristic of the patients 
The patients’ characteristics are summarized in Table I. The differences in the median ages or smoking 
history of Controls, Smokers and subjects with COPD were not statistically significant. As expected, FEV1% 
after bronchodilators as well as FEV1%/FVC were significantly lower in COPD patients than HS (p<0.001)  and 
C (p < 0.001). 
3.2. PGE2, VEGF, and IL-8 levels in human lung fibroblasts 
The concentrations of PGE2 in supernatants from lung fibroblasts of COPD patients were significantly 
higher than in supernatants obtained from C. HS showed higher PGE2 levels compared to C, but no statistically 
significant difference was observed (Figure 1A).  
VEGF concentration were higher in supernatants from lung fibroblasts of both HS and COPD when 
compared to C (Figure 1B), while only the concentrations of IL-8 in supernatants from lung fibroblasts of COPD 
subjects showed statistically significant difference from C (Figure 1C).  
3.3. COX-1, COX-2, EP1, EP2, EP3 and EP4 protein expression and mRNA in human lung fibroblasts. 
Western blot analyses of COX-1 and COX-2 proteins in cell lysates showed a significant increase in 
COX-2 expression by lung fibroblasts of Smokers and COPD subjects when compared to Controls (Figure 2A), 
while no differences were observed in COX-1 expression. The expression of EP2 and EP4 receptors was also 
significantly higher in the cell protein extracts from lung fibroblasts of COPD subjects compared to both HS and 
C (Figure 2B), while the expression of EP1 and EP3 receptor was not different among the three groups (Figure 
2B). The changes in protein expression resulted associated with changes in transcription levels as confirmed by 
the analysis of COX-2, EP2 and EP4 mRNAs (Figure 3A-C). 
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3.4. VEGF and IL-8 release in stimulated HFL-1. 
Synthetic PGE2 (10-9 to 10-6 M, a range of concentrations likely to mimic the differences observed in the 
pulmonary microenvironment in the absence or presence of phlogosis and inflammatory cells [24]) dose-
dependently increased the production of VEGF and IL-8 in stimulated HFL-1 (Figure 4A-B). Interestingly, the 
maximal release of IL-8 was observed at the highest concentration of PGE2 tested (namely 10-6 M, Figure 4B), 
with the EC50 for this effect certainly higher than 10-7 M, while the maximal efficacy on VEGF release was 
already observed at the PGE2 concentration of 10-7 M, with the concentration of 10-8 M representing the EC50 for 
this effect of PGE2 (Figure 4A). 
In order to assess if this differential effect could be observed also using biologically synthesized PGE2 we used 
supernatants of lung fibroblasts presenting either low (<10-9 M) or high (>10-8 M) concentrations of PGE2 to 
challenge HFL-1 cells. The results obtained showed that both COPD fibroblasts supernatants presenting low and 
high PGE2 concentrations significantly increased the production of VEGF (Figure 5A-B top panel). The 
supernatants of COPD lung fibroblasts showing high levels of PGE2 also increased the production of IL-8 in 
stimulated HFL-1 cells (Figure 5B bottom panel) while, according to the different potency observed using 
synthetic PGE2, no increase was observed using supernatants with low PGE2 concentrations (Figure 5A bottom 
panel). Finally, depleting the PGE2 present in the supernatants of COPD lung fibroblasts significantly decreased 
their ability to induce the production and release of VEGF or IL-8 in HFL-1 stimulated with supernatants from 
lung fibroblasts showing high levels of PGE2 (Figure 5C bottom panel). 
 
3.5. EP receptors role in the production of VEGF and IL-8 by PGE2 
To confirm the role of EP receptors in the production of VEGF (1) and IL-8 generated by PGE2 
stimulation, we used specific agonists and antagonists for the different EP receptor subtypes. The specific EP2 
receptor agonists Butaprost (10-6 M) significantly increased the production of VEGF as well as that of IL-8 in 
HFL-1, while the EP1/EP3 receptor agonist Sulprostone (10-5 M) did not affect the release of either VEGF or IL-
8 in HFL-1 (Figure 6A). Interestingly, the preincubation of HFL-1 with the specific EP4 receptor antagonist AH-
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23848 (10-5 M) caused a modest, but significant, reduction of the production of VEGF in HFL-1 stimulated 
with supernatants from COPD fibroblasts compared to baseline conditions, while the use of EP1 receptor 
antagonist SC-19220 (10-5 M) was ineffective (Figure 6B).  
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4. Discussion and Conclusions 
The results of this study provide evidence that lung fibroblasts from COPD patients show increased 
expression of COX-2, EP2, and EP4 receptors, and are able to affect their own production of VEGF and IL-8 
through the synthesis of different concentrations of PGE2. Indeed, in an autocrine/paracrine fashion, nanomolar 
levels of PGE2 are able to increase the production of VEGF, but over 20 folds higher concentrations are needed to 
also affect IL-8 release. Both effects appear to be associated to the activation of EP2, and possibly EP4, receptors 
on human fibroblasts. In light of these activities, we suggest that COX-2 expression/PGE2 synthesis together with 
enhanced expression of EP2/EP4 receptors might represent a switch factor from modulation/maintenance of 
pulmonary microvasculature to inflammation in COPD airways. Important pharmacological implications of these 
findings are associated to cyclooxygenases inhibition by NSAIDs.  
COPD is a disease state characterized by airflow limitation not fully reversible by bronchodilators. The 
airflow limitation is usually progressive and is associated to an abnormal inflammatory response of the lungs to 
noxious particles or gases, primarily cigarette smoking [25]. Pulmonary fibroblasts confer structural support to the 
lung connective tissue and play a role in stimulating and amplifying inflammatory signals through the expression 
of COX-2 and of microsomal prostaglandin E2 synthase in response to cigarette smoke [1]. Cigarette smoke, the 
major risk factor of COPD, also promotes the induction of COX-2 and PGE2 receptor expression in neutrophils 
and alveolar macrophages (AM), therefore contributing to the proinflammatory effects of PGE2 in the airways of 
COPD subjects [24,26]; indeed a significant overlap with minor, but statistically significant, differences was 
observed between HS and COPD subjects in terms of COX-2 and PGE2, but clearcut increases, in agreement with 
previously published data [27], were observed in COPD subjects only for EP2 and EP4 expressions, both as 
mRNA and protein, suggesting that the increase in PGE2-dependent IL-8 formation may be the result of 
concomitant higher PGE2 concentration and enhanced receptor expression when compared to C.,  
Fibroblasts are the major mesenchymal cells present within the interstitium of the lung and have been shown 
to be a major source of VEGF [4]. VEGF in the lung is required to maintain endothelial cell survival of pulmonary 
capillaries and therefore a normal alveolar wall [28], but VEGF is also an extremely potent pro-angiogenic factor, 
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and relatively small changes in its concentrations may promote pathological blood vessel expansion. 
Nevertheless the concentrations of VEGF, while higher than C, were not different in supernatants from HS and 
COPD subjects leading to hypothesis that the observed increase may represent the homeostatic response to 
smoking-induced hypoxia, leaving the IL-8 as a marker of the crossing into the COPD chronic inflammatory state. 
We certainly cannot exclude that VEGF may also participate in the inflammatory and fibrotic response observed in 
COPD, but, as recently reported [29], a synergistic effect can be hypothesized to occur when both VEGF and IL-8 
are on-board, while the role of VEGF as an homeostatic response factor may prevail in HS.  
A relevant number of ex vivo and in vitro studies have shown PGE2 to be important in airway inflammation 
and remodeling: PGE2 can modulate extracellular matrix deposition and inflammatory cytokine release, such as 
IL-6 and IL-8, in primary human airway smooth muscle cells and fibroblasts [17]. Indeed, we confirmed that 
synthetic PGE2 also stimulates human fibroblasts to release IL-8, but we found that higher concentrations were 
necessary when compared to that inducing the release of VEGF. These results were confirmed using supernatants 
from COPD lung fibroblasts containing lower (<10-9 M) and higher (>10-8 M) PGE2 concentrations, to stimulate 
the production of VEGF and IL-8 in HFL-1. Indeed, while both groups of supernatants were able to generate 
consistent concentrations of VEGF in stimulated HFL-1 cells, only supernatants with higher concentrations of 
PGE2 were capable of increasing the release of IL-8.  
It must be noted that the final concentrations of VEGF and IL-8 observed using the COPD fibroblast 
supernatants to challenge the HFL-1 cells represents the sum of the amounts synthesized by HFL-1 cells and the 
amounts already present in the supernatant; nevertheless the concentrations observed using the fibroblast 
supernatant resulted higher (by approximately 25% for VEGF and 40% for IL-8) than those observed challenging 
HFL-1 cells with synthetic PGE2. We certainly cannot exclude the presence in the supernatant of factor(s) that may 
potentiate the activity of PGE2 or further contribute to stimulate the formation of VEGF and IL-8, and this may be 
particularly relevant for the latter, given that the depletion of PGE2 from the supernatant only inhibited the increase 
in IL-8 formation by approximately 50%, even if the high variability observed in this measurement may limit the 
relevance of these considerations.  
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Although we cannot rule out the contribution of other eicosanoids (including lipoxygenase-derived 
autacoids [30]), taken together, the findings of our research work suggest and support a role of PGE2 as mediator 
capable of switching the activity of fibroblast from homeostatic maintenance of alveolar endothelium through the 
production of VEGF to an inflammatory cytokine-releasing phenotype supporting the synthesis of IL-8. 
HFL-1-cells are widely used normal human fetal lung fibroblasts known to express all four EP receptors [3]. 
Nevertheless, through the use of selective agonists and antagonist we confirmed the involvement of EP2 receptor, 
and possibly EP4, in the production of VEGF and IL-8 production from lung fibroblasts stimulated with PGE2. 
These results provide additional support to the evidence that the increase of cAMP and, possibly, the activation of 
PKA, are involved in the activation of fibroblasts to release both VEGF and IL-8.  
Previously published evidence showed the increased expression of EP2 and EP4 receptors in COPD [27], as 
well as the ability of cigarette smoke to induce VEGF release from fibroblasts [31] or the positive correlation 
between PGE2 and VEGF [4], but with the present work we provide evidence that different levels of PGE2 
production, as a result of COX-2 expression, can differentiate between the homeostatic pro-angiogenic or the pro-
inflammatory role of this prostanoid, underlining its critical role in normal physiology as well as in COPD 
pathophysiology.  
In conclusion we found that PGE2 biosynthesis and activity are enhanced in lung fibroblasts from COPD 
patients, as a result of an increase in COX-2, EP2 and, possibly, EP4 expression. PGE2 appeared to differentially 
affect the production of VEGF and of IL-8, with higher concentrations needed to steer fibroblasts toward the 
production of inflammatory cytokines during airway inflammation in COPD patients. As a result, while a basal 
production of PGE2 may have an homeostatic role driving the production of VEGF, the increased expression of 
COX-2 and of EP receptors may turn PGE2 into a pro inflammatory factor in COPD subjects. Significant 
inhibition of PGE2 production by NSAIDs may therefore result beneficial in reducing PGE2 concentrations to 
levels observed in basal conditions, reducing IL-8 production without affecting VEGF levels. 
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Tables 
 
Table I: Demographic characteristics of patients 
 Control 
n=6 
Smoker 
n=6 
COPD 
n=8  
Overall  
p value  
Sex, male/female 4/2 4/2 6/2  
Age, yr  64.5 ± 5.8  69.4 ± 7.5  66.3 ± 13.2  N.S. 
FEV1, % predicted 100 ± 9.4  93.3 ± 8.2  72.8 ± 17.5  p < 0.001  
FEV1/FVC, %  95.3 ± 4.9  92.4 ± 7.4  65.9 ± 3.5  p < 0.001 
Smoking, pack/yr 0  54.3 ± 26.2  65.7 ± 21.8  p < 0.001 
     
Data are shown as mean±S.D. Abbreviations: FEV1 = forced expiratory volume in 1 s; FVC = forced vital 
capacity. Statistical analysis for multiple comparisons was performed by Kruskal-Wallis test 
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Captions to Illustrations 
Figure 1: PGE2 (Panel A), VEGF (Panel B), and IL-8 (Panel C) concentrations in supernatants of cultured lung 
fibroblasts from control subjects (n=6), smoker (n=6) and COPD patients (n=8). Box plot represents median and 
IQ range. Statistical analysis was performed by ANOVA and Fisher’s PLSD correction. 
Figure 2: COX-1, COX-2, EP1, EP2, EP3, and EP4 protein expression in cultured lung fibroblasts from control 
subjects (n=6), smoker (n=6) and COPD patients (n=8). The results were expresses in arbitrary densitometric units 
(ADU) corrected against the density of β-actin bands. Panel A: COX-1 (top panel) and COX-2 (middle panel) and 
representative gel images of COX-1 and COX-2 (bottom panel). Panel B: EP1 and EP2 (top panels), EP3 and EP4 
(middle panels) and representative gel images of EP1, EP2, EP3, and EP4 (bottom panel). Statistical analysis was 
performed by ANOVA and Fisher’s PLSD correction. 
Figure 3: COX-2, EP2, EP4 gene expression in cultured lung fibroblasts from control subjects (n=3), smoker 
(n=5) and COPD patients (n=6). Data are expressed as fold increase versus the control group that was chosen as 
the reference group (see Materials and Methods for details). Statistical analysis was performed by Kruskal-Wallis 
test and Mann-Whitney U test. 
Figure 4: PGE2 stimulates VEGF and IL-8 release in human fetal lung fibroblasts (HFL-1) in a dose-dependent 
manner. Cultured HFL-1 were stimulated with different concentrations of PGE2 (10-9 M to 10-6 Μ) for 18 hrs. At 
the end of stimulation, cell supernatants were collected for VEGF (Panel A) and IL-8 (Panel B) analysis by ELISA 
(See Methods for details). The results were expressed as mean±SD from four independent experiments. Statistical 
analysis was performed by ANOVA and Fisher’s PLSD correction. *p<0.05, **p<0.01, and ***p<0.001 vs basal;. 
Figure 5: VEGF and IL-8 production from human fetal lung fibroblasts (HFL-1) stimulated with supernatants of 
lung fibroblasts with low PGE2 level (<10-9 M, n=3), and with high PGE2 level (>10-8 M, n=3), (see Methods for 
details). Values are expressed as mean±SD Panel A: VEGF (pg/ml) (top) and IL-8 (pg/ml) (bottom) production 
after stimulation with and without supernatants of lung fibroblasts with low PGE2 level. Panel B: VEGF (pg/ml) 
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(top) and IL-8 (pg/ml) (bottom) production after stimulation with and without supernatants of lung 
fibroblasts with high PGE2 level and with supernatants depleted from PGE2. Statistical analysis was performed by 
ANOVA and Fisher’s PLSD correction. 
Figure 6: Effect of specific EP receptors agonists and antagonists on VEGF and IL-8 release from human fetal 
lung fibroblasts (HFL-1). HFL-1 cells were stimulated with the indicated agonists or with the supernatants of lung 
fibroblasts from COPD (see Methods for details). Values are expressed as mean±SD. Production of VEGF (Panel 
A) and IL-8 (Panel B) in the presence or absence of Butaprost (EP2 agonist) or Sulprostone (EP3 agonist). Panel 
C: Production of VEGF after stimulation with supernatants of lung fibroblasts from COPD in presence or absence 
of SC-19220 (EP1 antagonist) or AH-23848 (EP4 antagonist). Statistical analysis was performed by ANOVA and 
Fisher’s PLSD correction. 
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